AstraZeneca, a British pharmaceutical company, said on May 7 that there has been a surplus of available vaccines since the outbreak of COVID-19, and the company has begun to remove NewCrown vaccines globally. The company said in a statement that its decision was based on commercial considerations. With the development of a variety of vaccines to respond to the variant COVID-19, there has been a surplus of available booster needles, which has led to a decline in the demand for the company's COVID-19 vaccine Vaxzevria. Therefore, AstraZeneca has begun to recycle vaccines globally and will also revoke the marketing authorization of vaccines in Europe. AstraZeneca admitted in a legal document submitted to the court earlier this year that its vaccine "can cause thrombosis and thrombocytopenia in rare cases, and its pathogenic mechanism is not yet clear." However, AstraZeneca stated that the decision to remove the vaccine this time is not related to court cases or the company's recognition that the vaccine may cause side effects in some recipients.